See more : US Foods Holding Corp. (USFD) Income Statement Analysis – Financial Results
Complete financial analysis of Genetron Holdings Limited (GTH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Genetron Holdings Limited, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- TDK Corporation (TTDKY) Income Statement Analysis – Financial Results
- Digital Domain Holdings Limited (2975.HK) Income Statement Analysis – Financial Results
- VaporBrands International, Inc. (VAPR) Income Statement Analysis – Financial Results
- SinoPac Financial Holdings Company Limited (2890.TW) Income Statement Analysis – Financial Results
- Zvi Sarfati & Sons Investments & Constructions Ltd. (SRFT.TA) Income Statement Analysis – Financial Results
Genetron Holdings Limited (GTH)
About Genetron Holdings Limited
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 650.71M | 531.95M | 424.49M | 323.43M | 225.18M | 101.03M |
| Cost of Revenue | 369.28M | 193.98M | 164.27M | 178.44M | 132.45M | 74.21M |
| Gross Profit | 281.43M | 337.97M | 260.22M | 144.99M | 92.73M | 26.82M |
| Gross Profit Ratio | 43.25% | 63.53% | 61.30% | 44.83% | 41.18% | 26.55% |
| Research & Development | 290.29M | 253.95M | 149.00M | 91.70M | 71.41M | 45.78M |
| General & Administrative | 266.91M | 227.00M | 126.32M | 117.17M | 88.23M | 45.49M |
| Selling & Marketing | 364.56M | 343.16M | 246.96M | 253.56M | 182.47M | 94.57M |
| SG&A | 631.47M | 570.16M | 373.28M | 370.73M | 270.71M | 140.06M |
| Other Expenses | -8.71M | -5.33M | -8.53M | -10.85M | -233.63M | -258.11M |
| Operating Expenses | 913.05M | 818.78M | 513.75M | 451.58M | 332.19M | 181.01M |
| Cost & Expenses | 1.28B | 1.01B | 678.02M | 630.01M | 464.64M | 255.22M |
| Interest Income | 2.86M | 20.50M | 28.33M | 441.00K | 1.55M | 513.00K |
| Interest Expense | 111.49M | 5.25M | 5.63M | 5.40M | 0.00 | 669.00K |
| Depreciation & Amortization | 85.39M | 20.50M | -2.80B | -319.22M | 27.86M | 20.61M |
| EBITDA | -651.24M | -460.32M | -201.69M | -625.81M | -212.21M | -134.08M |
| EBITDA Ratio | -83.94% | -86.53% | -718.18% | -193.49% | -197.04% | -397.06% |
| Operating Income | -631.62M | -480.82M | -253.53M | -306.59M | -232.98M | -152.54M |
| Operating Income Ratio | -97.07% | -90.39% | -59.73% | -94.79% | -103.46% | -150.98% |
| Total Other Income/Expenses | -108.69M | 21.04M | -2.80B | -366.94M | -225.53M | -268.10M |
| Income Before Tax | -810.63M | -502.60M | -3.07B | -676.03M | -464.99M | -420.64M |
| Income Before Tax Ratio | -124.58% | -94.48% | -723.00% | -209.02% | -206.50% | -416.34% |
| Income Tax Expense | 73.26M | -64.19M | -2.87B | -354.54M | -232.02M | -257.44M |
| Net Income | -883.89M | -438.40M | -198.11M | -321.49M | -464.99M | -420.64M |
| Net Income Ratio | -135.84% | -82.41% | -46.67% | -99.40% | -206.50% | -416.34% |
| EPS | -9.53 | -4.76 | -3.29 | -4.65 | -6.73 | -6.22 |
| EPS Diluted | -9.53 | -4.76 | -3.29 | -4.65 | -6.73 | -6.22 |
| Weighted Avg Shares Out | 92.80M | 92.11M | 60.28M | 69.07M | 69.07M | 67.68M |
| Weighted Avg Shares Out (Dil) | 92.80M | 92.11M | 60.28M | 69.07M | 69.07M | 67.68M |
Genetron Health to Present at the SVB Leerink CybeRx Series: Liquid Biopsy & Oncology Dx Summit
Genetron Health Presented Its Proprietary Early Screening Technology Mutation Capsule at Science/AAAS Webinar
Genetron Health Reports Unaudited Fourth Quarter and Full Year 2020 Financial Results, and Provides 2021 Revenue Guidance
Genetron Health Releases New Data Results of HCCscreen™ for Liver Cancer Early Screening in China
Genetron Health to Present at Science/AAAS Webinar About Early Cancer Screening on March 31
Genetron Health to Announce Fourth Quarter and Full Year 2020 Unaudited Financial Results and Host Investor Call on March 25, 2021
Genetron Health to Announce Fourth Quarter and Full Year 2020 Unaudited Financial Results and Host Investor Call on March 25, 2021
Genetron Health's Early Liver Cancer Screening Research Results Included in First Prevention and Treatment Guidelines for Patients in China
Genetron Health to Release Thirteen Research Findings at 21st World Conference on Lung Cancer
Genetron Health to Present at BTIG Early Cancer Screening, Diagnostics Reimbursement and Genomic Tools KOL Day on Jan. 22, 2021
Source: https://incomestatements.info
Category: Stock Reports